Evidence Explorer / Evidence record

MS-N007 · Literature searched October 13, 2026 · Appraised October 13, 2026 · Joint pain

Evidence at a glance

• Population: 226 postmenopausal women with early-stage breast cancer, taking an aromatase inhibitor, with baseline worst-joint-pain score at least 3 of 10.
• Intervention: true acupuncture (110), sham acupuncture (59) or waitlist control (57). True and sham groups received two sessions weekly for six weeks, then weekly for six more weeks.
• Six-week average effect: worst pain fell 2.05 points with true acupuncture, 1.07 with sham and 0.99 with waitlist. Adjusted differences were 0.92 points versus sham (95% CI 0.20–1.65) and 0.96 versus waitlist (95% CI 0.24–1.67).
• Responder result: a two-point improvement occurred in 58.0% with true acupuncture, 33.3% with sham and 31.4% with waitlist.
• Durability: at 52 weeks, adjusted worst-pain differences remained about one point in favor of true acupuncture, although some participants in every group received additional acupuncture after week 24.

What can we conclude?

Acupuncture improves aromatase-inhibitor joint pain for some patients. The group-average advantage was statistically significant but below the trial’s prespecified two-point threshold for a clinically meaningful difference. The responder analysis is more intuitive: compared with sham, the absolute increase in two-point responders was 24.7 percentage points (95% CI 8.8–40.5). The SIO–ASCO guideline therefore recommends acupuncture for this specific symptom with moderate recommendation strength. Results should remain attached to this trained, standardized protocol and early-stage breast-cancer population.

Important limits

Sham acupuncture produced substantial improvement, so attention, expectation and nonspecific needling effects matter. The trial population was 88% White, limiting generalizability. At 52 weeks, 191 of 226 randomized participants were evaluable, and crossover acupuncture after week 24 complicates long-term comparisons. The study did not test adherence to endocrine therapy, recurrence or survival.

Safety and practical context

Grade 1 bruising was more common with true than sham acupuncture (47% versus 25%). Serious complications are uncommon with a qualified practitioner using sterile, single-use needles, but low platelets, neutropenia, anticoagulants, active infection, healing wounds, ports and lymphedema precautions require discussion. New focal bone pain, neurologic symptoms, fever or trauma still need medical evaluation. Do not stop an aromatase inhibitor without the oncology team.

Funding and conflicts: The trial was funded through National Cancer Institute support. The original report noted NCI grant support for one investigator and no other disclosed conflicts.

Questions for the care team

• Does the pain pattern need imaging or another evaluation first?
• Are blood counts, anticoagulants and treatment-related precautions compatible with acupuncture now?
• Is there an oncology-experienced licensed practitioner or program using a studied protocol?
• What improvement in pain and function would count as worthwhile after six weeks?

Sources

• SWOG S1200 six-week randomized trial — PMID 29998338; DOI 10.1001/jama.2018.8907; NCT01535066
• SWOG S1200 52-week follow-up — PMID 36367721
• SIO–ASCO integrative pain guideline — PMID 36122322; DOI 10.1200/JCO.22.01357
• NCCIH acupuncture safety overview — checked October 13, 2026

Connected reviews

• Tart cherry for AI joint pain
• Vitamin D for AI joint pain
• Acupuncture for dry mouth

Learn how to judge a study · Return to the evidence map

This evidence brief is educational, not a personal treatment recommendation. Research schedules are not prescribing instructions. Symptom benefit does not establish tumor response, recurrence prevention or survival benefit.